ArticleArthritis research & therapy2006
A promoter haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population.
Article in Arthritis research & therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis.Genes and immunity · 2008Pooled it
- Recent advances and evolving concepts in Still's disease.Nature reviews. Rheumatology · 2024Review
- Biological treatment in resistant adult-onset Still's disease: A single-center, retrospective cohort study.Archives of rheumatology · 2022Article
- The Role of Interleukin 18/Interleukin 18-Binding Protein in Adult-Onset Still's Disease and Systemic Juvenile Idiopathic Arthritis.Journal of clinical medicine · 2022Review
- Activation mechanisms of monocytes/macrophages in adult-onset Still disease.Frontiers in immunology · 2022Review
- Article
- Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.International journal of inflammation · 2012Article
- Functional promoter haplotypes of interleukin-18 condition susceptibility to severe malarial anemia and childhood mortality.Infection and immunity · 2011Article
- Genetic association analyses of atopic illness and proinflammatory cytokine genes with type 1 diabetes.Diabetes/metabolism research and reviews · 2011Article
- Adult-onset Still's disease.Rheumatology international · 2010Review
- Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.Arthritis research & therapy · 2010Article
- Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.Journal of clinical immunology · 2009Article
- Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.The Journal of infectious diseases · 2008Article
- A comprehensive review of the genetics of juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2008Article
- The spectrum of autoinflammatory diseases: recent bench to bedside observations.Current opinion in rheumatology · 2008Review
- Interleukin-18 genetics and inflammatory disease susceptibility.Genes and immunity · 2007Review
- Single Nucleotide Polymorphism of IL-18 (Rs 1946519) in Recurrent Aborted Iraqi Women and Its Association with Toxoplasmosis.Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, we reported that genetic polymorphisms within the human IL18 gene were associated with disease susceptibility to adult-onset Still's disease (AOSD), which is characterized by extraordinarily high serum levels of IL-18. Because high serum IL-18 induction has also been observed in the systemic type of juvenile idiopathic arthritis (JIA), we investigated whether similar genetic skewing is present in this disease. Three haplotypes, S01, S02, and S03, composed of 13 genetic polymorphisms covering two distinct promoter regions, were determined for 33 JIA patients, including 17 with systemic JIA, 10 with polyarthritis, and 6 with oligoarthritis. Haplotypes were also analyzed for 28 AOSD patients, 164 rheumatoid arthritis (RA) patients, 102 patients with collagen diseases, and 173 healthy control subjects. The frequency of individuals carrying a diplotype configuration (a combination of two haplotypes) of S01/S01 was significantly higher in the JIA patients, including all subgroups, than in the healthy controls (P = 0.0045, Fischer exact probability test; odds ratio (OR) = 3.55, 95% confidence interval (CI) = 1.55-8.14). In patients with systemic JIA, its frequency did not differ statistically from that of normal controls. Nevertheless, it is possible that haplotype S01 is associated with the phenotype of high IL-18 production in systemic JIA because the patients carrying S01/S01 showed significantly higher serum IL-18 levels compared with patients with other diplotype configurations (P = 0.017, Mann-Whitney U test). We confirmed that the frequency of the diplotype configuration of S01/S01 was significantly higher in AOSD patients than in healthy control subjects (P = 0.011, OR = 3.45, 95% CI = 1.42-8.36). Furthermore, the RA patients were also more predisposed to have S01/S01 (P = 0.018, OR = 2.00, 95% CI = 1.14-3.50) than the healthy control subjects, whereas the patients with collagen diseases did not. In summary, the diplotype configuration of S01/S01 was associated with susceptibility to JIA as well as AOSD and RA, and linked to significantly higher IL-18 production in systemic JIA. Possession of the diplotype configuration of S01/S01 would be one of the genetic risk factors for susceptibility to arthritis in the Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.